Jakarta, 16 April 2026 – Sartorius, a leading international partner to the biopharmaceutical research and the manufacturing industries, and i3L University, a premium life sciences higher education and research institute, have signed a Memorandum of Understanding (MoU) to collaborate on the development of training programs for the biopharmaceutical manufacturing sector in Southeast Asia.

Under the non-binding agreement, Sartorius Stedim Singapore Pte. Ltd. and i3L University will jointly design and implement practice-oriented training formats aimed at developing industry-ready talent, equipping trainees with essential competencies in biopharmaceutical manufacturing, and expanding access to high-quality technical training throughout Indonesia and the broader Southeast Asian region.

i3L University will take the lead in organizing the programs, engaging participants, and providing academic and logistical support. Sartorius will contribute its technical expertise, bioprocess know-how, and training content, based on its extensive experience working with biopharmaceutical manufacturers worldwide.

The MoU takes effect on April 9, 2026, and the agreement was signed by representatives of Sartorius Stedim Singapore Pte. Ltd. and i3L University, underscoring their shared commitment to supporting the development of a robust biopharmaceutical ecosystem in Southeast Asia.

About Sartorius

Sartorius is a leading international partner to the biopharmaceutical research and manufacturing industries. The company supports customers with a broad product portfolio focused on single-use solutions for the safer, faster, and more sustainable production of biotech drugs, vaccines, and cell and gene therapies, as well as focuses on innovative laboratory instruments and consumables for research and quality assurance laboratories. With around 60 production and sales locations worldwide, the Gottingen-based company has a strong global presence.